Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Propanc Biopharma said its PRP candidate produced more than 90% mean tumor growth inhibition in pancreatic cancer models. The release also compared the preclinical data with Revolution Medicines' recently approved daraxonrasib.
Propanc Biopharma said it reported preclinical PRP data in advanced pancreatic cancer models and plans a multicenter, open-label Phase 1b first-in-human study in Q1 2027, with PRP holding FDA Orphan Drug Designation for pancreatic cancer.